Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Vote for AI research shortlisted for the BHF Research Story of the Year award

Voting is open! Some of our British Heart Foundation funded research has been shortlisted for the BHF Research Story of the Year award. Discover more and vote for our work into developing an AI tool to predict people’s risk of having a heart attack years before it happens.

Research that focuses on developing an artificial intelligence (AI) tool that can predict people's risk of having a heart attack up to 10 years before it happens, is up for the award.

In the first real-world trial of the AI tool in the NHS, the tool was found to improve treatment for up to 45 per cent of those examined, indicating that this technology could potentially save thousands of lives.

Find out more about our BHF-funded research project and cast your vote.

Similar stories

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

How body fat is stored across organs may reveal hidden health risks, study suggests

University of Oxford researchers have found that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.

New RDM course builds capacity in hyperpolarised MRI

Researchers, students and imaging specialists from across the UK and Europe recently completed a new training programme in hyperpolarised MRI at Oxford. This course builds expertise in a rapidly developing imaging technology with applications across healthcare and biomedical research.

First real-world trial shows AI could reduce need for contrast injections in heart MRI scans

The technology could make advanced heart MRI faster, cheaper and more accessible.

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Professor Jan Rehwinkel receives funding to tackle viral threats

A research project led by Professor Jan Rehwinkel is one of three innovative Oxford-led projects aimed at transforming how we protect against respiratory viruses, which have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Similar stories

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

How body fat is stored across organs may reveal hidden health risks, study suggests

University of Oxford researchers have found that how fat accumulates in the body is just as important for identifying different health risks as a person’s overall weight.

New RDM course builds capacity in hyperpolarised MRI

Researchers, students and imaging specialists from across the UK and Europe recently completed a new training programme in hyperpolarised MRI at Oxford. This course builds expertise in a rapidly developing imaging technology with applications across healthcare and biomedical research.

First real-world trial shows AI could reduce need for contrast injections in heart MRI scans

The technology could make advanced heart MRI faster, cheaper and more accessible.

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Professor Jan Rehwinkel receives funding to tackle viral threats

A research project led by Professor Jan Rehwinkel is one of three innovative Oxford-led projects aimed at transforming how we protect against respiratory viruses, which have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).